Keyphrases
Metastatic Melanoma
61%
Melanoma
59%
Pembrolizumab
50%
Programmed Death-ligand 1 (PD-L1)
37%
Advanced Melanoma
37%
Clinical Outcomes
34%
Overall Survival
25%
T Cells
19%
Immune Checkpoint Inhibitors
17%
Ipilimumab
17%
Melanoma Patients
16%
Cancer Immunotherapy
14%
Confidence Interval
14%
CD8+ T Cells
13%
Complete Response
13%
Chimeric Antigen Receptor T Cells (CAR-T)
12%
Metastasis
12%
Median Overall Survival
12%
Metastatic Uveal Melanoma
11%
Objective Response Rate
10%
Durable Response
10%
United States
10%
Temozolomide
9%
Brain Metastases
9%
Response Rate
9%
Tumor Response
9%
Immune-related Adverse Events
9%
Hazard Ratio
9%
Median Progression-free Survival
9%
Progression-free Survival
8%
Chemotherapy
8%
Soluble PD-L1 (sPD-L1)
8%
Tumor
8%
Systemic Immunity
8%
CD5+
8%
Monotherapy
8%
B-cell Lymphoproliferative Disorder
8%
Independent Prognostic Factor
8%
Neoadjuvant
8%
Baseline Tumor Size
8%
Everolimus
8%
Vemurafenib
8%
Immune Checkpoint Inhibitor Therapy
8%
Sex Differences
8%
Adverse Events
8%
Mayo Clinic
8%
In Cancer
8%
Response Evaluation Criteria in Solid Tumors (RECIST)
7%
Tumor Cells
7%
Anti-programmed Death 1
7%
Medicine and Dentistry
Melanoma
100%
Pembrolizumab
42%
Malignant Neoplasm
40%
Neoplasm
39%
Metastatic Melanoma
37%
Overall Survival
32%
Diseases
25%
Immune Checkpoint Inhibitor
24%
T Cell
15%
Progression Free Survival
14%
Metastatic Carcinoma
13%
B Cell
12%
Brain Metastasis
12%
Melanoma Skin Cancer
11%
Clear Cell Renal Cell Carcinoma
11%
Metastatic Uvea Melanoma
11%
Programmed Death 1 Ligand 1
10%
Cytotoxic T-Cell
10%
Targeted Therapy
10%
Immunotherapy
10%
Systemic Immunity
10%
Biopsy Technique
9%
Biological Marker
9%
Lung Cancer
9%
Prognostic Factor
9%
Cancer Therapy
9%
Bevacizumab
9%
Adverse Event
9%
Ipilimumab
8%
Monotherapy
8%
Stereotactic Body Radiation Therapy
8%
Lymphoproliferative Disease
8%
Chemoimmunotherapy
8%
Vemurafenib
8%
Immune-Related Adverse Events
8%
Lymphocyte
8%
Clinical Trial
8%
Chimeric Antigen Receptor T-Cell
7%
B-Cell Chronic Lymphocytic Leukemia
7%
Cytokine
7%
Radiation Therapy
6%
Cancer
6%
Uvea Melanoma
6%
Hazard Ratio
5%
Programmed Death 1 Receptor
5%
Cisplatin
5%
Positron Emission Tomography-Computed Tomography
5%
Carboplatin
5%
Paclitaxel
5%
Biological Rhythm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
74%
Pembrolizumab
46%
Neoplasm
43%
Malignant Neoplasm
39%
Overall Survival
35%
Metastatic Melanoma
35%
Ipilimumab
15%
Progression Free Survival
15%
Diseases
15%
Chemotherapy
14%
Adverse Event
14%
CD8 Antigen
12%
Solid Malignant Neoplasm
10%
Programmed Death 1 Ligand 1
9%
Bevacizumab
9%
Brain Metastasis
8%
Everolimus
8%
Chimeric Antigen Receptor
8%
Survival Rate
8%
Immune Checkpoint Inhibitor
7%
Clinical Trial
7%
Renal Cell Carcinoma
7%
Immunotherapy
7%
Metastatic Uvea Melanoma
6%
Paclitaxel
5%
Carboplatin
5%
Temozolomide
5%
Uvea Melanoma
5%
Lung Cancer
5%
Programmed Death 1 Receptor
5%
Disease Exacerbation
5%